MacDonald D, Jian Y, Gordan A, Mahendra P, Oskam R, Palmer P, Franks C, Barrett A J.
Recombinant interleukin 2 for acute myeloid leukaemia in first complete remission.
Leukaemia Research, 1990; 14: 967-973
Bashey A, Owen I, Lucas G F, Amphlett N W, Jones M M, Lawal A, McMullin M F, Mahendra P, Tyfield L A, Hows J M.
Late onset immune pancytopenia following bone marrow transplantation.
British Journal of Haematology, 1991; 78: 268-274
McMullin M F, Mahendra P, Hain R, Barrett A J.
Myelodysplasia as the initial presentation of Fanconi’s anaemia in a phenotypically normal child.
Clinical and Laboratory Haematology, 1991; 13: 387-389
Pyruvate kinase deficiency, in association with glucose-6 phosphate dehydrogenase deficiency.
British Medical Journal, 1992; 305: 760-762
Rege K, Powles R, Norton J, Mahendra P, Mitchell P, Agrawal S, Mehta J, Treleaven J.
An unusual presentation of acute myeloid leukaemia with pericardial and pleural effusions due to granulocytic sarcoma.
Leukemia and Lymphoma, 1993; 11: 305-307
Mahendra P, Barfoot R K, Bell J B G, Powles R, Treleaven J, Millar J L, Millar B C.
TGFß1 and IL-4 have opposing effects on the proliferation of chronic phase chronic myeloid leukaemic cells stimulated by G-CSF in vitro.
Leukemia and Lymphoma, 1994; 12: 449-455
Mahendra P, Bedlow A J, Ager S, Ancliff P J, Wraight E P, Marcus R E.
Technetium (99mTc) labelled white cell scanning, 51Cr EDTA and 14C mannitol-labelled intestinal permeability studies: non-invasive methods of diagnosing intestinal graft-versus host disease.
Bone Marrow Transplantation, 1994; 13: 835-837
Mahendra P, Ager S, Bedlow A J, Bloxham D, Green A R, Marcus R E.
Two unusual neurological presentations of granulocytic sarcoma in Philadelphia positive chronic myeloid leukaemia.
Leukemia and Lymphoma, 1994; 15: 351-355
Mahendra P, Harman K, Phillips M G, Gunning K, Marcus R E. Rapid progression of “retinoic acid syndrome” in the hypogranular variant of acuute promyelocytic leukaemia despite treatment with dexamethasone and conventional chemotherapy.
Clinical and Laboratory Haematology, 1994; 16: 371-374.
In-vitro effects of cytokines on normal and myeloid leukaemic haemopoiesis.
MD thesis, 1995; University of Glasgow.
Scott MA, Ager S, Jestice H K, Mahendra P, Marcus R E.
The failure to mobilise and harvest PBPCs does not necessarily preclude the use of high-dose therapy and autologous stem cell rescue.
Bone Marrow Transplantation, 1995; 15: 487-488 (letter)
MacGowan J R, Mahendra P, Ager S, Marcus R E.
Thrombocytopenia and spontaneous rupture of the spleen associated with infectious mononucleosis.
Clinical and Laboratory Haematology, 1995, 17: 93-94.
Ager S, Scott M A, Mahendra P, Richards M, Jestice H K, Boraks P, Baglin T P, Marcus R E.
Peripheral blood stem cell transplantation after high-dose therapy in patients with malignant lymphoma: a retrospective comparison with autologous bone marrow transplantation.
Bone Marrow Transplantation, 1995, 16: 79-83.
Scott M A, Ager S, Apperley J F, Jestice H K, Bloxham D M, Boraks P, Mahendra P, Marcus R E.
Peripheral blood progenitor cell harvesting in multiple myeloma and malignant lymphoma.
Leukemia and Lymphoma, 1995, 19: 479-484.
Ager S, Mahendra P, Jestice H K, Scott M A, Marcus R E.
Non-cryopreserved peripheral stem cells for autologous transplantation.
Bone Marrow Transplantation, 1995, 16: 633-634 (letter)
Mahendra P, Hood I M, Johnson D, Ethell M, Jestice H K, Scott M A, Barker P, Bass G, Baglin T P, Marcus R E.
Autografting for multiple myeloma: a 5 year experience at a single institution.
Bone Marrow Transplantation, 1995, 16: 759-763.
Ager S, Mahendra P, Bass G, Baglin T P, Marcus R E.
High-dose carmustine, etoposide and melphalan (BEM) with autologous stem cell transplantation; a dose:toxicity study.
Bone Marrow Transplantation, 1996, 17; 335-340.
Mahendra P, Johnson D, Scott M A, Jestice H K, Ager S, Hood I M, Bass G, Barker P, Baglin T P, Marcus R E.
Peripheral blood progenitor cell transplantation: a single centre experience comparing two mobilisation regimens in 67 patients.
Bone Marrow Transplantation, 1996, 17; 503-508.
Mahendra P, Hood I M, Bass G, Patterson P, Marcus R E.
Severe haemosiderosis post allogeneic bone marrow transplantation.
Haematological Oncology, 1996, 14; 33-35.
Mahendra P, Keeling D M, Hood I M, Baglin T P, Marcus R E.
Fatal thromboembolism in a patient with acute promyelocytic leukaemia treated with a combination of all-trans retinoic acid and aprotonin.
Clinical and Laboratory Haematology, 1996, 18:51-52.
Mahendra P, Hood I M, Lee M, Mewar D, Bass G, Flower C D R, Wilson C B,
Marcus R E.
Interstitial pneumonitis as a late complication after high-dose cyclophosphamide/thiotepa and peripheral blood progenitor cell rescue for carcinoma of the breast.
Clinical Oncology, 1996, 8: 198-200.
Mahendra P, Jacobson S K, Ager S, Bass G, Barker P, Johnson D, Baglin T P, Marcus R E.
Short course intravenous antibiotics in conjunction with oral quinolone prophylaxis in the treatment of neutropenic fever in autologous bone marrow or stem cell transplant recipients.
Acta Haematologica, 1996, 96: 64-67.
Mahendra P, Johnson D, Hood I M, Scott M A, Barker P, Bass G, Jestice H K, Bloxham D M, Boraks P, Wimperis J Z, Baglin T P, Marcus R E.
High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients.
Bone Marrow Transplantation, 1996, 17: 973-978
Richards E M, Jestice H K, Mahendra P, Scott M A, Marcus R E, Baglin T P.
Measurement of reticulated platelets following peripheral blood progenitor cell and BMT: implications for marrow reconstitution and the use of thrombopoietin.
Bone Marrow Transplantation, 1996, 17: 1029-1033
Mahendra P, Richards E M, Sinclair P, Marcus R E, Nacheva E.
t(9;13)(q34;q12) translocation associated with myelodysplastic syndrome persisting 4 years post autologous bone marrow transplantation despite achieving haematological remission.
Clinical and Laboratory Haematology, 1996, 18: 121-122
Hood I M, Mahendra P, McNeil K, Marcus R E.
Hodgkin’s Disease post cardiac transplantation: A report of two cases.
Clinical and Laboratory Haematology, 1996, 18: 115-116
Somers L J, Shaw B, Lyn B E, McMillan A M, Mahendra P
Meningeal myeloma in the absence of systemic disease and as the initial feature of disease progression.
Clinical and Laboratory Haematology, 1998,20: 189-190
Rahman S L, Mahendra P, Nacheva E, Sinclair P, Arno J, Marcus R E.
Achievement of complete cytogenetic remission after two very low-dose donor leucocyte infusions in a patient with extensive cGVHD relapsing in accelerated phase post allogeneic BMT for CML.
Bone Marrow Transplantation, 1998, 21: 955-956.
Scott M A, Gandhi M K, Jestice H K, Mahendra P, Bass G., Marcus R E.
A trend towards an increased incidence of chronic graft-versus-host allogeneic following
allogeneic peripheral blood progenitor cell transplantation: a case controlled study.
Bone Marrow Transplantation, 1998,22: 273-276.
Boraks P, Seale J, Price J, Bass G, Ethell M, Keeling D, Mahendra P, Baglin T, Marcus R
Prevention of central venous catheter associated thrombosis using minidose warfarin in patients with haematological malignancies.
British Journal of Haematology, 1998, 101: 483-486.
Double autografting for multiple myeloma – is two better than one?
Leukaemia and Lymphoma, 1999, 7: 29-34.
Hepatic veno-occlusive disease following stem cell transplantation.
Thrombus, 1999, 3: 1-3.
Tauro S, Toh V, Osman H, Mahendra P
Varicella zoster meningoencephalitis following dermatomal zoster in an alloBMT patient: a role for early intravenous acyclovir in localised zoster infections.
Bone Marrow Transplantation, 2000, 26, 795-796.
Tauro S, Dobie D, Richardson G, Hastings M, Mahendra P
Recurrent penicillin resistant pneumococcal sepsis after matched unrelated donor transplantation for refractory T-NHL.
Bone Marrow Transplantation, 2000,26, 1017-1019.
Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabart S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JCW, Schey S, Mahendra P, Morgan G, Hale G, Waldmann H, Ruiz de Elvira M, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S.
In vivo Campath-1H prevents graft-versus-host disease following non myeloablative stem cell transplantation and limits transplant related mortality.
Blood, 2000, 96, 2419-2425.
Cwynarski K, Ainsworth J, Cobbold M, Wagner S, Mahendra P, Apperley J, Goldman J, Craddock C, Moss PAH.
Direct visualisation of cytomegalovirus specific T-cell reconstitution following allogeneic bone marrow transplantation.
Blood, 2001, 97, 1232-1240
Tauro S and Mahendra P
Resolution of sarcoidosis post-allogeneic bone marrow transplantation with donor lymphocyte infusions.
Bone Marrow Transplantation, 2001, 27, 757-759.
Zaidi Y, Hastings M, Murray J, Rowena JM Kursheid M, Mahendra P.
Quinolone resistance in neutropenic patients in 2 very different haematology units.
Clinical and Laboratory Haematology, 2001, 23, 39-4
Kottaridis PD, Milligan DW, Chopra R, Chakraverty RK, Chakrabarti S, Robinson S, Peggs K, Verfuerth S, Pettengell R, Marsh JCW, Schey S, Mahendra P, Morgan GJ, Hale G, Waldmann H, Ruiz de Elvira MC, Williams CD, Devereux S, Linch DC, Goldstone AH, Mackinnon S.
In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem cell transplantation.
Cryotherapy, 2001, 3, 197-201.
Lush RJ, Haynes AP, Byrne JL, Cull GM, Carter GI, Pagliuca A, Parker JE, Mufti G, Mahendra P, Craddock CF, Liu Yin JA, Garg M, Prentice HG, Potter MN, Russell NH.
Allogeneic stem cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with donor lymphocyte infusion.
Cryotherapy 2001, 3, 203-210.
Harris E, Mahendra P, Linch D, Chatterjee R.
Gynaecomastia with hypogonadism and androgen oestrogen imbalance in recipients of high dose chemotherapy or chemoradiotherapy.
Bone Marrow Transplantation, 2001, 28, 1141-1144.
Harris E, Jackson N, Jones L, Mahendra P
Burkitt’s lymphoma: single centre experience with modified BFM protocol.
Clinical and Laboratory Haematology, 2002, 24, 111-114.
Chakraverty R, Peggs K, Chopra R, Milligan DW, Kottaridis PD, Verfueth S, Geary J, Branson K, Chakrabarti S, Mahendra P, Craddock C, Parker A, Hunter A, Hale G, Waldmann, H, Williams CD, Yong K, Linch DC, Goldstone AH, Mackinnon S.
Limiting transplant-related mortality following unrelated donor stem cell transplantation by using a non-myeloablative conditioning regimen.
Blood, 2002, 99, 1071-1078..
Beswick SJ, Jones EL, Mahendra P, Marsden JR
Chloroma (aleukaemic leukaemia cutis) initially diagnosed as cutaneous lymphoma.
Clinical and Experimental Dermatology, 2002, 27, 272-274.
Chakrabarti S, Kottaridis PD, Peggs K, Ogormon P, Chakraverty R, Marshall T, Osman H, Gentle T, Mahendra P, Craddock C, Walderman H, Hale G, Fegan CD, Goldstone AH, Linch DC, Chopra R, Mackinnon S, Milligan DW.
Reduced GvHD but a high incidence of cytomegalovirus infection and delayed reconstitution of T-cell subsets after nonmyeloablative haematopoietic stem cell transplants using Campath 1H (anti CD52 antibody)
Blood, 2002, 12; 4357-4363
Spanswick VJ, Craddock C, Sekhar M, Mahendra P, Shankaranarayana P, Hughes RG, Hochhauser D, Hartley JA
Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma.
Blood, 2002, 100; 224-229.
Peggs KS, Paneesha S, Kottaridis PD, Chakraverty RK, Tobias G, Reilly M, Mahendra P, Yong K.
Peripheral blood stem cell transplantation for POEMS syndrome.
Bone Marrow Transplantation, 2002, 30; 401-404
Clark FJ, Freeman L, Dzionek A, Schmitz J, McMullan, Simpson P, Mason J, Mahendra P, Craddock C, Griffiths M, Moss P, Chakraverty R.
Origin and subset distribution of peripheral blood dendritic cells in patients with chronic GvHD.
Transplantation 2003, 75, 221-225.
Tauro S, Clark FJ, Lipkin , Richards N, Mahendra P.
Recovery of renal function after autologous stem cell transplantation in myeloma patients with end-stage renal failures.
Bone Marrow Transplantation, Bone Marrow Transplantation; 2002; 30; 471-473
High-hyperploidy in Ph positive acute lymphoblastic leukaemia: case-report and review of literature.
Tauro S, McMullan D, Griffiths M, Craddock C, Mahendra P.
Bone Marrow Transplantation, 2003, 9; 763-766.
Tauro S, Shankararanarayanan P, Nitu-Whalley IC, Duncan N, Begum G, Craig JI, Marcus RE, Craddock CF, Mahendra P.
Stem cell transplantation after salvage therapy with high-dose cytarabine and amsacrine in adults with high-risk leukaemia.
Bone Marrow Transplanation, 2003, 32; 273-278.
Faulkner RD, Craddock CF, Bryne JL, Mahendra P, Haynes AP, Prentice HG, Potter M, Pagliuca A, Ho A, Devereux S, McQuaker G, Mufti G, Liu Yin J, Russell NH.
BEAM-Campath reduced intensity allogeneic stem cell transplantation for lymphoproliferatice diseases: GvHD, toxicity and survival in 65 patients.
Blood, 2004, 103; 428-434
Cook MA, milligan DW, Fegan CD, Darbyshire PJ, Mahendra P, Craddock CF, Moss PA, Briggs DC.
The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling haemopoietic stem cell transplantation for myeloid leukaemia.
Blood, 2004, 103; 1521-1526.
Clark FJ, Gregg R, Piper K, Dunnion D, Freeman L, Griffiths M, Begum G, Mahendra P, Craddock C, Moss P, Chakraverty R.
Chronic GvHD is associated with increased numbers of peripheral blood CD4+, CD25 high regulatory T cells.
Blood, 2004, 103; 2410-2416
Wandroo F, Augustson B, Cook M, Craddock C, Mahendra P
Successful use of Campath-1H in the treatment of steroid refractory liver GvHD
Bone Marrow Transplantation, 2004: 34: 285-7.
Morris E, Thomson K, Craddock C, Mahendra P, Milligan D, Cook G, Smith G, Parker P, Schey S, Snowden J, Chopra R, Hatton C, Tighe J, Hunter A, Peggs K, Linch D, Goldstone A, Mackinnon S.
Outcome following Alemtuzumab (Campath-1H) containing reduced intensity allogeneic transplant regimen for relapsed and refractory non-Hodgkins lymphoma
Blood, 2004, 104; 3865-71
Successful allogeneic stem cell transplantation in patients with poor-risk leukaemia and prior invasive fungal infection.
Mehta P, Augustson, Krishnamurthy S, Jacob A, D Roy, Olliff J, Cook M, Craddock C, Mahendra P
Bone Marrow Transplantation, 2004: 34:825-826
“Floating” teeth at presentation in sporadic Burkitt’s lymphoma.
Murrin RJ, Mahendra P
British Journal of Haematology, 2004: 127: 1
Peggs S, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, Craddock C, Pettengell R, Dogan A, Thomson K, Morris E, Hale G, Waldmann H, Goldstone A, Linch D, Mackinnon S.
Clinical evidence of a graft-versus-Hodgkins lymphoma effect after reduced intensity allogeneic transplantation.
Hunter HM, Peggs K, Powles R, Rahemtulla A, Mahendra P, Cavenagh J, Littlewood T, Potter M, Hunter A, Pagliuca A, Williams C, Cook G, Towlson K, Marks D, Russell NH.
The effects of the conditioning regimen on outcome following allogeneic haemopoietic stem cell transplantation for myeloma
British Journal for Haematology, 2005:128:496-502.
Raj K, Narayanan S, Augustson B, Ho A, Mehta P, Duncan N, Tauro S, Mahendra P, Craddock C, Mufti G.
Rituximab is effective in management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation.
Bone Marrow Transplantation, 2005:35; 299-301.
Wandroo FA, Mahendra P, Khuroo RA, Neilson J
Plasma cell leukaemia presenting with polyarthralgia and phalangeal lytic lesions.
Clinical and Laboratory Haematology, 2005: 27: 203-205
Cobbold M, Khan N, Tauro S, McDonald D, Osman H, Assenmacher M, Billingham L, Crawley C, Olavarria E, Goldman J, Chakraverty R, Mahendra P, Craddock C, Moss P.
Direct adoptive transfer of CMV-specific CTL to stem cell transplant patients following selection by HLA-peptide tetramers.
Journal of Experimental Medicine, 2005: 202; 379-386
CD8+ T cells specific for cancer-germline gene antigens are found in many patients with multiple myeloma and their frequency correlates with disease burden.
Goodyear O, Piper K, Khan N, Starczynski, Mahendra P, Pratt G, Moss P
Blood, 2005; 106; 4217-4224
Tauro S, Craddock C, Peggs K, Begum G, Chopra R, Littlewood T, Parker A, Marsh J, Cook G, Hale G, Snowdon J, Milligan D, Hunter A, Russell N, Goldstone A, Mahendra P, Linch D, Mackinnon S
Outcome of allogeneic stem cell transplantation in adults with high risk acute myeloid leukaemia and myelodysplasia using an alemtuzemab based reduced-intensity conditioning regimen.
Journal of Clinical Oncology, 2005; 23; 9387-9393
Increased acute GvHD and higher transplant-related mortality in non-caucasians undergoing standard sibling allogeneic stem cell transplantation.
Karanth M, Begum G, Cook M, Porter C, Lister N, Gray J, Lawson S, Darbyshire P, Craddock C, Mahendra P
Bone Marrow Transplantation, 2006; 37: 419-423
Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation.
Cook M, Briggs D, Craddock C, Mahendra P, Milligan D, Fegan C, Darbyshire P, Lawson S, Boxall E, Moss P.
Blood; 2006; 107: 1230-1232
Reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation in relapsed and refractory Hodgkin lymphoma: impact of alemtuzumab and donor lymphocyte infusions on long-term outcomes.
Peggs K, Sureda A, Caballero D, Hunter A, Urbano-Ispizua A, Cavet J, Ribera J, Parker A, Canales M, Mahendra P, Garcia-Conde J, Milligan D, Sanz G, Thomson K, Arranz R, Goldstone A, Alvarez A, Linch D, Sierra J, Mackinnon S.
British Journal of Haematology, 2007; 139; 70-80.
CXC10-CXCR3 interactions play an important role in the pathogenesis of acute GvHD in the skin following allogeneic stem-cell transplantation.
Piper KP, Horlock C, Curnow SJ, Arrazi J, Nicolls S, Mahendra P, Craddock C, Moss PAH
Blood, 2007; 110; 3827-3832
The role of rituximab post stem cell transplantation.
Tawana K and Mahendra P
Lymphoma Forum, November 2007, epub
Post-transplant lymphoproliferative disorder followed by Hodgkins disease in a renal transplant recipient.
Lokare A, Chagnati S, Lipkin G, Roberts C, Mahendra P
Transplantation, 2008; 85; 1219-20
Treatment of oral mucositis after peripheral SCT with ATL-104 mouthwash: results from a randomized, double blind, placebo-controlled trial.
Hunter A, Mahendra P, Wilson K, Fields P, Cook G, Peniket A, Crawley C, Hickling R, Marcus R.
Bone Marrow Transplantation, 2009; 43; 563-9
Secondary anchor polymorphism in the HA-1 minor histocompatibility antigen critically affects MHC stability and TCR recognition.
Nicholls S, Piper KP, Mohammed F, Dafforn TR, Tenzer S, Salim M, Mahendra P, Craddock C, van Endert P, Schild H, Cobbold M, Engelhand VH, Moss PA, Wollcox BE.
Proceedings of the National Academy of Sciences 2009; 106; 3889-94
Early reconstitution of effector memory CD4+ CMV -specific T cells protects against CMV reactivation following allogeneic SCT.
Pourgheysari B, Piper KP, McLarnon A, Arrazi J, Bruton R, Clark F, Cook M, Mahendra P, Craddock C, Moss PA.
Bone Marrow Transplantation 2009; 43; 853-61
Head and neck lymphomas
In Stell and Maran’s Textbook of Head and Neck. Editors Watkinson J and Gilbert R
Dose-intensified treatment of Burkitts/Burkitt-like lymphoid malignancy in young adults (<50years): a comparison of two adapted BFM protocols.
Tauro S, Cochrane L, Lauritzsen G, Baker L, Delabie J, Roberts C, Mahendra P, Holte H
Amercian Journal of Hematology, 2010; 85; 261-263
CD8 (+) T-cell immunity against cancer-testis antigens develops following allogeneic stem cell transplantation and reveals a potential mechanism for the graft-versus leukemia effect.
McLarnon A, Piper KP, Goddyear OC, Arrazi JM, Mahendra P, Cook M, Clark F, Pratt G, Craddock C, Moss PA.
Haematologica 2010; 95; 1572-1578.
BCSH Guideline: Diagnosis and Management of Chronic Graft- versus-Host Disease
Fiona L.Dignan1, 2, Persis Amrolia3, Andrew Clark4 , Jacqueline Cornish OBE5, Graham Jackson6, Prem Mahendra7, Julia J.Scarisbrick8, Peter C. Taylor9, Bronwen E. Shaw 1,10, Michael N. Potter1 on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology and the British Society for Blood and Marrow
Bristish Journal of Haematology; 2012; 158; 46-61
BCSH Guideline: Organ-Specific Management and Supportive Care in Chronic Graft-versus -Host Disease
Fiona L.Dignan1, 2, Julia J.Scarisbrick3, Jacqueline Cornish OBE4, Andrew Clark5, Persis Amrolia6, Graham Jackson7, Prem Mahendra8, Peter C. Taylor9, Pallav Shah10, Sue Lightman11, Farida Fortune12, Christopher Kibbler13, Jervoise Andreyev14, Assunta Albanese15, Nedim Hadzic16, Michael N. Potter1, Bronwen E.Shaw 1,17 on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology and the British Society for Blood and Marrow Transplantation.
British Journal of Haematology; 2012; 62-72
BCSH Guideline: Diagnosis and Management of Acute Graft-versus-Host Disease
Fiona L.Dignan1, 2, Andrew Clark3, Persis Amrolia4, Jacqueline Cornish OBE5, Graham Jackson6, Prem Mahendra7, Julia J.Scarisbrick8, Peter C.
Taylor9, Nedim Hadzic10 Bronwen E.Shaw 1,11, Michael N. Potter1 on behalf of the Haemato-oncology Task Force of the British Committee for Standards in Haematology and the British Society for Blood and Marrow Transplantation
British Journal of Haematology; 2012; 158; 30-45
Post-transplant T cell chimersim predicts graft versus host disease but not disease relapse in patients undergoing an alemtuzumab reduced intensity conditioned allogeneic transplant.
Nikolousis E, Robinson S, Nagra S, Brookes C, Kinsella F, Tauro S, Jeffries S, Griffiths M, Mahendra P, Cook M, Paneesha S, Lovell R, Kishore B, Chaganti S, Malladia R, Raghaven M, Moss P, Milligan D, Craddock C.
Leukaemia Research; 2013; 37: 5610565.
Outcome of EAM conditioned autologous haematopoietic SCT for lymphoma: A matched pairs retrospective single centre analysis.
Loke A, Ward J, Mahendra P, Chaganti S, Malladi R.
Bone Marrow Transplantation; 2013; 10
Kikuchi-Fujimoto disease: a rare but importamt differential diagnosis for lymphadenopathy
Srikantharajah M, Mahendra P, Vydianathh B, Lowe GC
BMJ Case Rep 2014; Sept 8